Internalization of Recombinant Imiglucerase into Mouse Peritoneal Macrophages and L929 Mouse Fibroblasts
Enzyme replacement therapy (ERT) is one of the most efficient treatments for lysosomal storage diseases. Type 1 Gaucher disease is caused by β-glucocerebrosidase enzyme deficiency, which may be compensated for by intravenous infusions of imiglucerase—a recombinant enzyme. Imiglucerase targets macrop...
Main Authors: | I. V. Lyagoskin, M. S. Pantyushenko, O. M. Strizhakova, N. K. Kudina, E. Yu. Prudnikova, P. V. Chichkanova, S. G. Abbasova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2020-03-01
|
Series: | Биопрепараты: Профилактика, диагностика, лечение |
Subjects: | |
Online Access: | https://www.biopreparations.ru/jour/article/view/270 |
Similar Items
-
Enucleated L929 mouse fibroblasts support invasion and multiplication of Shigella flexneri 5a
by: D. Yamamoto, et al.
Published: (2006-06-01) -
Results of a phase I open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of Glurazyme® (imiglucerase) in comparison with the reference product in healthy volunteers
by: S. B. Fitilev, et al.
Published: (2019-12-01) -
The antimicrobial peptide gramicidin S alters proliferation and inhibits adhesion of L929 cell line fibroblasts
by: N. M. Alabedalkarim, et al.
Published: (2023-08-01) -
Quantitative Phase Imaging to Study the Effect of Sodium Dodecyl Surfactant on Adherent L929 Fibroblasts on Tissue Culture Plates
by: Sonthikan Sitthisang, et al.
Published: (2021-11-01) -
Bioimpedance Analysis of L929 and HaCaT Cells in Low Frequency Range
by: Teixeira Viviane S., et al.
Published: (2018-09-01)